Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General
Executive Summary
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.
You may also be interested in...
US Biosimilars Strength Rides On The Wings Of Oncology Launches
Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.
Biosimilar Incentives: US Senate Republicans ‘Leery’ Of Out-Of-Pocket, Shared Savings Policies
Senate Finance Committee staffer explains Republicans are inclined to support more moderate approaches in the near term as the 'bigger ideas' for promoting biosimilars evolve.
Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says
But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.